Oxford BioMedica PLC (OXB.L) Says ProSavin Promising; Shares Double
10/15/2009 7:28:21 AM
More...
|
Oxford BioMedica PLC (OXB.L) Announces Update on Phase I/II Study of ProSavin(R) in Parkinson's Disease
7/13/2009 12:51:33 PM
More...
|
The Court Supports Bavarian Nordic (BAVA.CO)'s Decision to Start Patent Infringement Case Against Oxford BioMedica PLC (OXB.L)
5/11/2009 7:35:39 AM
More...
|
Oxford BioMedica PLC (OXB.L) and Sanofi-Aventis (France) (SASY.PA) Enter New Collaboration Worth $50 Million
4/30/2009 7:24:18 AM
More...
|
Oxford BioMedica PLC (OXB.L): Preliminary Results For The Year Ended 31 December 2008
3/12/2009 12:16:47 PM
More...
|
Oxford BioMedica PLC (OXB.L) FY Revenue Up to 18.4 Million Stage
3/12/2009 7:59:32 AM
More...
|
Oxford BioMedica PLC (OXB.L) Receives Further Investment Under Agreement Led by the Foundation Fighting Blindness
2/5/2009 1:58:21 PM
More...
|
Bavarian Nordic (BAVA.CO)'s Case Against Oxford BioMedica PLC (OXB.L)
1/12/2009 9:49:19 AM
More...
|
Oxford BioMedica PLC (OXB.L) Announces Six-Month Efficacy Results With Low Dose of ProSavin(R) in Phase I/II Trial in Parkinson’s Disease
11/19/2008 12:05:20 PM
More...
|
Oxford BioMedica PLC (OXB.L) Announces Two Scientific Presentations of ProSavin in Parkinson's Disease
11/14/2008 12:45:11 PM
More...
|
|